ライフサイエンスコーパス: PBSC

1 PBSC (> or = 7.5 x 10(8) nucleated cells/kg) were collec

2 PBSC collection was done after two induction cycles.

3 PBSC collections were initiated when the WBC count recov

4 PBSC donors were treated with 5 to 7 days of filgrastim

5 PBSC harvests were processed each day on a single avidin

6 PBSC patients were discharged from hospital earlier than

7 PBSC transplant recipients were older, and were more lik

8 PBSC transplants contained higher doses of DC2 than marr

9 PBSC were collected from 229 patients from the purged gr

10 PBSC were enriched for the CD34+ population with and wit

11 PBSC were mobilized with high dose cyclophosphamide and

12 PBSCs are a preferred source of stem cells for many type

13 PBSCs mobilized by GRObeta (GRObeta(Delta4)/CXCL2(Delta4

14 PBSCs mobilized by GRObeta(Delta4) alone or with G-CSF c

15 PBSCs mobilized with pSCF/pIL-3 were infused into an SLA

16 PBSCs were collected after mobilization with chemotherap

17 PBSCs were mobilized at steady state (n = 2), after gran

18 It is concluded that (1) PBSC collection was feasible and stable engraftment occu

19 luate the peripheral blood lymphocytes of 22 PBSC donors and 22 matched controls at 5 time points ove

20 port a prospective study of 2726 BM and 6768 PBSC donors who underwent collection from 2004 to 2009.

21 To achieve 90% PBSC survival rate for a 2.0-GBq injection dose, PBSC do

22 Eight additional PBSC donors provided a single sample at 12 months.

23 the recommendation for ATG to be added after PBSC transplantation, no obvious benefit was identified

24 apy supported by bone marrow collected after PBSC collection failure.

25 grade 1 and two with grade 2) 100 days after PBSC repeat infusion, compared with three patients (two

26 apy (28.8-39.0 Gy) a median of 45 days after PBSC repeat infusion.

27 Hematopoietic recovery was faster after PBSC transplantation.

28 ilar, but chronic GVHD risk was higher after PBSC transplantation (relative risk [RR], 1.85; 95% CI,

29 CI, 1.07 to 1.79; P = .01) were higher after PBSC transplantation.

30 These data suggest poorer outcomes after PBSC compared with BM transplantation in children after

31 ocyte components and clinical outcomes after PBSC transplantation.

32 All PBSC donors but only 79% of marrow donors reported good

33 We studied 639 allogeneic PBSC collections performed in 412 white, 75 black, 116 H

34 ransplant-related mortality after allogeneic PBSC transplantation will require more effective strateg

35 a high risk of chronic GVHD after allogeneic PBSC transplantation, which compromised the performance

36 tation from HLA-identical donors, allogeneic PBSC transplantation from HLA-identical donors is associ

37 Following allogeneic PBSC transplant, patients who received greater than 5 x

38 ngraftment after nonmyeloablative allogeneic PBSC transplantation.

39 ears to be safe in donors with SCT, allowing PBSC use for transplantation in patients with sickle cel

40 ant differences were observed between BM and PBSC donors regarding pain, blood allotransfusion, durat

41 ) can be safely administered with GM-CSF and PBSC support.

42 n be safely administered with filgrastim and PBSC support.

43 loablation with oral busulfan (16 mg/kg) and PBSC transplantation.

44 Both marrow and PBSC donors reported minimal fluctuation in symptoms mea

45 We prospectively compared bone marrow and PBSC for allogeneic transplantation.

46 tment was comparable between bone marrow and PBSC recipients (P > .1).

47 time integration of the organ dose rate and PBSC distribution rate.

48 The ATG and PBSCs were the only variables that independently decreas

49 imilar to that observed following autologous PBSC transplant, with an absolute neutrophil count (ANC)

50 n cost per patient was $4,000 for autologous PBSC and $11,000 for allogeneic BM transplants.

51 nalysis, the use of CD34-selected autologous PBSC after high-dose therapy was associated with a marke

52 by the infusion of CD34-selected autologous PBSC were assessed for the development of CMV disease in

53 ve patients receiving unselected, autologous PBSC, only 10 patients (4.2%) developed CMV disease, wit

54 Thus, prolonged engraftment of autologous PBSCs and continued expression of the transduced gene ca

55 nstituted with BALB/c (H-2(d))+BXSB (H-2(b)) PBSCs, in which the number of injected allogeneic progen

56 bone marrow/peripheral blood stem cells (BM/PBSCs), unrelated BM/PBSCs, and unrelated cord blood rec

57 al blood stem cells (BM/PBSCs), unrelated BM/PBSCs, and unrelated cord blood recipients.

58 other hand, increases in the number of BXSB PBSCs resulted in the transfer of lupus nephritis in BXS

59 es of (90)Y-2IT-BAD-m170 therapy followed by PBSC infusion.

60 CD34(+) peripheral blood stem cells (CD34(+)PBSCs) with lentivector-gp91(phox) or amphotropic oncore

61 gnificant ex vivo correction of X-CGD CD34(+)PBSCs (18% and 54% of cells expressing gp91(phox), assoc

62 Only lentivector transduced CD34(+)PBSCs under ex vivo conditions nonpermissive for cell di

63 ced CD34+ peripheral blood stem cells (CD34+ PBSCs) from this trial transplanted into nonobese diabet

64 n of NOD/SCID mouse repopulating X-CGD CD34+ PBSCs (14%-22% corrected human neutrophils; human cell e

65 ein to allow similar studies of normal CD34+ PBSCs, we show that progressively higher levels of gene

66 More than 80% of the PBMCs or CD34+ PBSCs from 7 different donors were beta-galactosidase-po

67 ed of autologous peripheral blood stem cell (PBSC) collection in 27, followed by transplantation in 2

68 rastim mobilized peripheral blood stem cell (PBSC) collections in unrelated volunteers.

69 ow (BM) and 6768 peripheral blood stem cell (PBSC) donors who underwent collection of PBSC or BM betw

70 studied whether peripheral blood stem cell (PBSC) graft iNKT-cell dose affects on the occurrence of

71 Unfractionated peripheral blood stem cell (PBSC) grafts contain measurable quantities of myeloma ce

72 human allogeneic peripheral blood stem cell (PBSC) grafts would reduce GVHD and provide sufficient nu

73 Peripheral-blood stem cell (PBSC) harvest and surgical resection of residual primary

74 e ameliorated by peripheral blood stem cell (PBSC) infusion.

75 Peripheral blood stem cell (PBSC) infusions are associated with complications such a

76 d feasibility of peripheral blood stem cell (PBSC) mobilization in 8 SCT subjects and 8 control subje

77 able estimate of peripheral blood stem cell (PBSC) mobilization response to granulocyte colony-stimul

78 ous schedules of peripheral blood stem cell (PBSC) reinfusion, granulocyte colony-stimulating factor

79 with autologous peripheral blood stem cell (PBSC) rescue is widely used for the treatment of maligna

80 doxorubicin and peripheral blood stem cell (PBSC) support in advanced medullary thyroid cancer (MTC)

81 nor T cells from peripheral blood stem cell (PBSC) transplant allografts ex vivo using an anti-CD25 i

82 ng an allogeneic peripheral blood stem cell (PBSC) transplant from an HLA-identical (n = 14) or a 5/6

83 Peripheral blood stem cell (PBSC) transplantation is successful in improving engraft

84 Peripheral blood stem cell (PBSC) transplantation may provide a strategy to decrease

85 Allogeneic peripheral blood stem cell (PBSC) transplants from HLA-identical siblings were perfo

86 sus conventional peripheral blood stem cell (PBSC) transplants from HLA-matched siblings were compare

87 ts of autologous peripheral blood stem cell (PBSC) transplants.

88 Autologous peripheral blood stem cell (PBSC)-supported high-dose melphalan is now considered st

89 38 marrow and 31 peripheral blood stem cell [PBSC]) donors participating in a randomized trial compar

90 Currently, peripheral blood stem cells (PBSC) are infused after myeloablative therapy, but the e

91 de (PTCY) using peripheral blood stem cells (PBSC) as a source of graft.

92 sed to mobilize peripheral blood stem cells (PBSC) from normal donors, has led to the use of PBSC as

93 Recipients of peripheral blood stem cells (PBSC) had faster recovery and fewer platelet transfusion

94 Peripheral blood stem cells (PBSC) have become the preferred source of stem cells for

95 Peripheral-blood stem cells (PBSC) may be used as an alternative to bone marrow (BM)

96 currently using peripheral blood stem cells (PBSC) mobilized by chemotherapy and recombinant growth f

97 n of allogeneic peripheral blood stem cells (PBSC) mobilized by either recombinant canine granulocyte

98 Peripheral blood stem cells (PBSC) obtained from granulocyte-colony stimulating facto

99 plantation with peripheral blood stem cells (PBSC) results in faster haematopoietic-cell repopulation

100 Human peripheral blood stem cells (PBSC) were obtained by leukapheresis from a human male d

101 eceived BM plus peripheral-blood stem cells (PBSC).

102 ed either BM or peripheral blood stem cells (PBSCs) according to center policy.

103 Mobilized peripheral blood stem cells (PBSCs) are widely used for transplantation, but mechanis

104 d peripheral blood hematopoietic stem cells (PBSCs) demonstrate accelerated engraftment compared with

105 in which human peripheral blood stem cells (PBSCs) differentiate along megakaryocytic as well as mye

106 tients received peripheral blood stem cells (PBSCs) from HLA-identical siblings, and 23 received bone

107 tients received peripheral blood stem cells (PBSCs) from matched-related donors, 2 received PBSCs fro

108 Peripheral blood stem cells (PBSCs) have been widely adopted as a source of stem cell

109 Although peripheral blood stem cells (PBSCs) have replaced bone marrow (BM) as the most common

110 most primitive peripheral blood stem cells (PBSCs) in PNH appear to be of normal phenotype.

111 SF) to mobilize peripheral blood stem cells (PBSCs) is increasing.

112 supported with peripheral-blood stem cells (PBSCs) is related to the dose of CD34(+) cells infused.

113 plus allogeneic peripheral blood stem cells (PBSCs) is sufficient to interrupt autoimmune processes i

114 atients who had peripheral-blood stem cells (PBSCs) mobilized with filgrastim or the sequential regim

115 Peripheral blood stem cells (PBSCs) mobilized with high-dose chemotherapy and hematop

116 l population of peripheral blood stem cells (PBSCs) of three asymptomatic HIV-1-infected individuals

117 ologous CD34(+) peripheral blood stem cells (PBSCs) that had been transduced ex vivo with a recombina

118 ical allogeneic peripheral blood stem cells (PBSCs) that were selected for CD34+ cells by an avidin-b

119 34(+) peripheral blood-mobilized stem cells (PBSCs) with retrovirus vector encoding wild-type (wt) CX

120 f HLA-identical peripheral-blood stem cells (PBSCs), and 675 recipients of unrelated donor BM transpl

121 MCs), and CD34+ peripheral blood stem cells (PBSCs).

122 lant from BM or peripheral blood stem cells (PBSCs).

123 f the graft was peripheral blood stem cells (PBSCs).

124 row (n = 93) or peripheral blood stem cells (PBSCs; n = 49).

125 ed peripheral blood progenitor (stem) cells (PBSCs) have recently become the preferred source for hem

126 (bone marrow vs peripheral blood stem cells [PBSCs]), age, sex, graft-versus-host disease (GVHD), ste

127 obilized blood (peripheral blood stem cells; PBSC) from cancer patients.

128 ychology and Behavioral Sciences Collection [PBSC]) was conducted from database inception to May 2012

129 In conclusion, PBSC collection in unrelated donors is generally safe, b

130 collected, a direct comparison of concurrent PBSC versus BM donation experiences has not been perform

131 -4 GVHD after reduced intensity conditioning PBSC h-HSCT, perhaps because of the combined effect of T

132 years (median, 46 years), given conventional PBSC transplants following high-dose conditioning and po

133 X (10% with > or = 50% tumor cytoreduction), PBSC mobilization with HDCTX should be limited to select

134 fter high-dose radioimmunotherapy can damage PBSCs if they are transfused too early.

135 ation and chemical lysis was used to deplete PBSC collections of monocytes, granulocytes, erythrocyte

136 ompared to recipients of non-T-cell-depleted PBSC autografts.

137 erly patients receiving selectively depleted PBSC transplants from HLA-identical sibling donors.

138 nts with high-risk leukemia with TN-depleted PBSC grafts following conditioning with total body irrad

139 All recipients of TN-depleted PBSCs engrafted.

140 s toxic conditioning regimens are developed, PBSC transplantation might provide a new solution to all

141 d successful engraftment of allogeneic donor PBSCs and the elimination of alloantibody.

142 Among obese donors, PBSC donors were at increased risk of grade 2 to 4 pain

143 survival rate for a 2.0-GBq injection dose, PBSC dosimetry suggested a time interval of 13 d after r

144 imetry that considers damage of PBSCs during PBSC circulation and residence in organs with high radio

145 starting with administration of filgrastim (PBSC donors) or after the marrow collection procedure.

146 he median time to progression from the first PBSC reinfusion was 49.5 weeks (range, 8 to 156+ weeks).

147 Hematopoietic recovery following PBSC is dependent on progenitor-cell number infused and

148 sed risk for SAEs (0.99% for BM vs 0.31% for PBSC; OR, 3.20; P < .001).

149 sed risk for SAEs (2.38% for BM vs 0.56% for PBSC; odds ratio [OR], 4.13; P < .001), and women were t

150 ion of adequate numbers of CD34(+) cells for PBSC infusion in patients with AB.

151 administration of G-CSF to normal donors for PBSC collection appears safe, longer follow-up is requir

152 veloping fatal GVHDLS was 62-fold higher for PBSC and 210-fold higher for BM as compared with CB.

153 veloped for optimizing the time interval for PBSC infusion after high-dose radionuclide therapy.

154 central venous catheter (CVC) placement for PBSC collection.

155 rax with hydrothorax after CVC placement for PBSC collection.

156 nterval of 13 d after radioimmunotherapy for PBSC infusion.

157 l use, but the optimal dose and schedule for PBSC collection are still being defined.

158 ed, but a quicker resolution of symptoms for PBSC donors.

159 assay, differed among clinical grafts: BM > PBSC > CB.

160 w that (1) multilineage engraftment of human PBSC can be achieved in the fetal rhesus recipient, (2)

161 Although cytokine stimulation of human PBSCs ex vivo led to a significant increase in CFU-MK, C

162 clusion, xenogeneic transplantation of human PBSCs into NOD/SCID mice provides an excellent in vivo m

163 cess wt CXCR4 expression by transduced human PBSCs enhanced marrow engraftment, but did not affect bo

164 rowth factors with proven utility to improve PBSC mobilization and maximize our PBSC procurement thro

165 lusion, higher doses of CD4(-) iNKT cells in PBSC grafts are associated with protection from aGVHD.

166 loited to reduce tumor cell contamination in PBSC harvests.

167 nd female genital tract was more frequent in PBSC recipients than in BM recipients.

168 H2 cells, an effect that may be important in PBSC transplantation.

169 In addition, cancer incidence in PBSC donors was less than that reported in the general p

170 edian CD34+ cell content was also similar in PBSCs collected from SCT versus control subjects, 6.8 ve

171 rget for G-CSF and GRObeta/GRObetaT-mediated PBSC mobilization and, importantly, that synergistic mob

172 Mixed PBSC transplantation (PBSCT) prevented the production of

173 The survival of mixed PBSC chimeras (BALB/c+BXSB-->BXSB) was 80% at the age of

174 ovided bone marrow and lenograstim-mobilised PBSC.

175 L2 and GRObetaT/CXCL2Delta4 rapidly mobilize PBSC equivalent to granulocyte colony-stimulating factor

176 We hypothesized that G-CSF-mobilized PBSC contain antigen-presenting cells, which prime T-lym

177 nonuclear cells (PBMCs) from G-CSF-mobilized PBSC donors.

178 udy, we investigated whether G-CSF-mobilized PBSC maintain their GVL effect in a murine allogeneic tr

179 cute GVHD after transplantation of mobilized PBSC were not different than previously reported for non

180 latelet recovery faster than G-CSF-mobilized PBSCs.

181 Furthermore, these cytokine-mobilized PBSCs demonstrate the potential to reconstitute hematopo

182 Cytokine-mobilized PBSCs were capable of hematopoietic reconstitution.

183 data suggest that GRObeta(Delta4)-mobilized PBSCs are superior in reconstituting long-term hematopoi

184 GRObeta(Delta4)-mobilized PBSCs did not migrate well to the chemokine stromal deri

185 an patients receiving sargramostim-mobilized PBSCs.

186 nt than previously reported for nonmobilized PBSC or marrow.

187 PBSCs, (2) MA + TBI + BM, (3) MA + nonTBI + PBSCs, (4) MA + nonTBI + BM, (5) reduced intensity condi

188 has led to tentative suggestions that normal PBSCs could be collected and used for autologous transpl

189 fully recovered at 24 weeks, whereas 100% of PBSC donors had recovered.

190 ll (PBSC) donors who underwent collection of PBSC or BM between 2004 and 2009 as part of a prospectiv

191 antly longer time interval for completion of PBSC collection than group 1 (median, 22 v 8 days; P = .

192 3 of nonrelapse causes (1 within 100 days of PBSC infusion) and 3 of disease progression.

193 ed with lower morbidity, shorter duration of PBSC mobilization, and comparable hematopoietic recovery

194 e sought to evaluate whether the infusion of PBSC grafts containing lysed red blood cells (RBCs) lead

195 Mobilization of PBSC was achieved with cyclophosphamide, etoposide, and

196 Mobilization of PBSC was achieved with either filgrastim alone or in com

197 il regarding individualized risk patterns of PBSC versus BM donation toxicity, suggesting donor profi

198 Immunomagnetic purging of PBSC for autologous stem-cell transplantation did not im

199 evelop in higher proportion in recipients of PBSC than in recipients of marrow.

200 arboplatin plus etoposide with reinfusion of PBSC.

201 CD34 selection of PBSC has been applied as a means of reducing contaminati

202 cytes were harvested on day 7 as a source of PBSC.

203 -CSF, followed by collections at the time of PBSC harvest (days 5-7) and at 2, 6, and 12 months after

204 Given the trend toward increased use of PBSC allografts in children, prospective clinical trials

205 C) from normal donors, has led to the use of PBSC as a major alternative to bone marrow for patients

206 marrow may confer some of the advantages of PBSCs without the risks of chronic GVHD.

207 Mobilization characteristics of PBSCs were determined in 2-5-month-old miniature swine.

208 Collection of PBSCs from cytokine-mobilized animals via an automated l

209 er somewhat in the number and composition of PBSCs and effector cells mobilized to the peripheral blo

210 ninvasive dosimetry that considers damage of PBSCs during PBSC circulation and residence in organs wi

211 hod considers a time-varying distribution of PBSCs and radioactivity in tissues.

212 The survival fractions of PBSCs in patients were determined as functions of the in

213 our laboratory, procurement of a megadose of PBSCs is necessary for on-going studies evaluating non-m

214 New strategies for rapid mobilization of PBSCs from normal donors using plerixafor have been repo

215 The radiosensitivity of PBSCs was determined by measuring survival of granulocyt

216 nic GVHD developed in 39 of 63 recipients of PBSCs and in 32 of 63 BM recipients who were alive and f

217 given 14 to 21 days apart with reinfusion of PBSCs.

218 These features enhance the safety of PBSCs directed gene therapy.

219 With the use of PBSCs, more than 90% of patients achieved complete donor

220 Despite lack of data on PBSC transplantation in children, there has been a chang

221 emotherapy regimens and patient variables on PBSC collections as measured by the yield of CD34+ cells

222 re infused with either bone marrow (n=19) or PBSC (n=20) after standard conditioning regimens in a do

223 eceived T cell-replete grafts of CB or BM or PBSC, the duration of GVHDLS-free survival of the chimer

224 o improve PBSC mobilization and maximize our PBSC procurement through an automated collection procedu

225 This study proposes to plan PBSC infusion time based on noninvasive dosimetry that c

226 or patients who received BM only and BM plus PBSC, respectively.

227 mprove engraftment, which suggests that poor PBSC mobilization usually indicates poor marrow function

228 neutrophil recovery was accelerated by post-PBSC G-CSF.

229 e factors, progenitor numbers returned, post-PBSC G-CSF, and hematologic recovery was performed in 81

230 Preharvested PBSCs were reinfused when the 90Y activity in the body w

231 for hematologic malignancies in G-CSF-primed PBSC donors.

232 The most primitive PBSCs (CD34+/CD38-) were almost all normal before G-CSF

233 ther non-purged or immunomagnetically purged PBSC.

234 reatment: 243 patients to receive non-purged PBSC and 243 to received purged PBSC.

235 Non-purged PBSC are acceptable for support of myeloablative therapy

236 e non-purged PBSC and 243 to received purged PBSC.

237 For purging, PBSC were mixed with carbonyl iron and phagocytic cells

238 Patients in cohorts A and C received PBSC on day 0; patients in cohorts B and D received 25%

239 Although the 2 cohorts received PBSC components with similar CD34(+) cell doses, the coh

240 Patients received PBSC transplants between 1993 to 1995 while BM patients

241 SCs) from matched-related donors, 2 received PBSCs from matched-unrelated donors, and 2 received stem

242 ith increasing numbers of children receiving PBSC allografts.

243 in determining the optimal time to reinfuse PBSCs for radiopharmaceuticals that have much a higher a

244 transplants with MA + nonTBI + BM and RIC + PBSCs had significantly lower risks of grades B-D AGVHD

245 I + BM, MA + nonTBI + BM, RIC + BM, or RIC + PBSCs had lower risks of grades B-D AGVHD than those in

246 , (5) reduced intensity conditioning (RIC) + PBSCs, and (6) RIC + BM.

247 suggested an interval about 7 d for the same PBSC survival rate.

248 y can also be achieved with CD34(+)-selected PBSC alone.

249 plit schedule reinfusion of CD34(+)-selected PBSC did not accelerate granulocyte recovery.

250 CD34(+)-selected PBSC rescue decreased the incidence of postreinfusion na

251 Subjects received CD34-selected PBSCs and a defined dose of TM purged of CD45RA+ TN.

252 e did a randomised study of tumour-selective PBSC purging in stem-cell transplantation for patients w

253 ble that transplantation of G-CSF-stimulated PBSC does not result in overwhelming acute GVHD because

254 d Nov 16, 2012, 174 patients with sufficient PBSCs were randomised to salvage ASCT (n=89) or cyclopho

255 Synergistic PBSC mobilization observed when G-CSF and GRObeta/GRObet

256 y to decide upon a minimum dose of syngeneic PBSCs to achieve the desired beneficial effects on autoi

257 ing (MA) with total body irradiation (TBI) + PBSCs, (2) MA + TBI + BM, (3) MA + nonTBI + PBSCs, (4) M

258 We conclude that PBSC and BM collection are safe procedures in children.

259 Several studies indicate that PBSCs confer survival advantages over bone marrow with m

260 Our small study indicates that PBSCs are better than bone marrow for allogeneic transpl

261 sis of our experience, we would suggest that PBSCs should be the stem cell source of choice in childr

262 The PBSC group had significantly faster neutrophil recovery

263 of grades 3 to 4 acute GVHD were 14% for the PBSC group and 33% for the BM group, P = .05).

264 ng grades 2 to 4 acute GVHD were 37% for the PBSC group and 56% for the BM group (P = .18), while the

265 ficantly increased numbers of T cells in the PBSC graft, acute graft-versus-host disease (GVHD) is no

266 In the PBSC group (n = 139), ATG was associated with a lower CI

267 higher in the bone-marrow group than in the PBSC group (p=0.01); all five relapses occurred among bo

268 s (0.04 vs 0.08, p=0.007) were higher in the PBSC group, and the proportion of patients with absolute

269 o 4.7 x higher numbers of CD34+ cells in the PBSC product than the same total dose given once a day (

270 ly measurement of the CD34(+) content of the PBSC collection was performed by a central laboratory us

271 Our studies suggested that the PBSC dosimetry method was more effective than the blood

272 ntainers for culture and transduction of the PBSCs.

273 received a reduced intensity conditioning to PBSC h-HSCT with cyclosporine and mycophenolate mofetyl

274 1995, 44 patients with MM were randomized to PBSC mobilization with either granulocyte colony-stimula

275 The radiation dose to PBSCs was determined by time integration of the organ do

276 optosis of neutrophils arising in transduced PBSC cultures even with stimulation by a CXCR4 agonist,

277 Thirty patients underwent PBSC collection with median 31.1 x 10(6) CD34+ cells/kg

278 lly delayed when compared with unmanipulated PBSC grafts; one patient required infusion of a reserve

279 h larger numbers of T cells in unmanipulated PBSCs than in bone marrow grafts.

280 We report results in 2408 unrelated PBSC donors prospectively evaluated by the National Marr

281 Reinfusion of 25% of unselected PBSC on day -2 (median, 2.26 x 10(8)/kg nucleated cells

282 gen desaturation in comparison to unselected PBSC reinfusion (P < or = .005 for each).

283 Five patients received back-up PBSC infusion because of delayed neutrophil or platelet

284 In summary, recipients of URD-PBSC HCT receiving preparative regimens differing in int

285 cell hematopoietic cell transplantation (URD-PBSC HCT) for acute myeloid leukemia, acute lymphoblasti

286 Using PBSCs from unrelated donors does not appear to be more b

287 ferences between the groups undergoing BM vs PBSC donation preclude direct risk comparisons between t

288 rombosis after donation was similar in BM vs PBSC donors.

289 In most patients whose PBSC collection contains less than 1 x 10(5)/kg GM-CFC,

290 12 to 20) and paclitaxel (250 mg/m(2)) with PBSC and GM-CSF repeated every 28 days.

291 and carboplatin/etoposide administered with PBSC support was relatively well tolerated.

292 cant contributor to toxicity associated with PBSC infusions.

293 nse received myeloablative chemotherapy with PBSC rescue and radiation to the presurgical primary tum

294 side, and cyclophosphamide chemotherapy with PBSC support was performed.

295 trial comparing allogeneic bone marrow with PBSC transplantation were studied.

296 ered as 24-hour infusions and supported with PBSC and filgrastim.

297 GM-CFC, six received high-dose therapy with PBSC alone and five had delayed engraftment.

298 nt autologous stem-cell transplantation with PBSC as randomly assigned after six cycles of induction

299 41% (P = .39) for patients transplanted with PBSC or BM, respectively.

300 317 patients undergoing transplantation with PBSCs from April 1991 to June 1997.